TLR4 and lymphoma: In fact, TLR4 is increasingly considered a promising therapeutic target for solid cancers, and TLR4 activation by low doses of endotoxic LPS from E.coli showed therapeutic promise in inhibiting the progression of osteosarcoma [115], lymphoma [137], subcutaneous glioma [138], and osteosarcoma [115].